Inoue S, Fukuda O, Tajima C, Tokunaga T, Nakayama M, Maeyama M
Gan To Kagaku Ryoho. 1982 Jul;9(7):1226-30.
Thirty-seven patients with advanced ovarian cancer were treated with futraful (FT-207) and esquinone (CQ). These patients had infiltrated tumors to the pelvic and peritoneal cavity and also distant metastasis, so they were not operated perfectly. There were evaluable 12 patients out of 37. FT-207 + CQ is an effective drug combination against advanced ovarian cancer with an overall response rete of 40.9%, a complete response rate of 4.5% (1/22), partial response rate of 36.4% (8/22), no change rate of 27.3% (6/22) and progressive rate of 31.8% (7/22). Patients with adenocarcinoma showed a response rate of 66.7% (8/12). According to the stage, the patients in stage III showed response rate of 50.0% (6/12), in stage IV showed a response rate of 37.5% (3/8). The total dose of FT-207 used in the study was 38.3g in the progressive disease group and 177.6 in the good response group. The group of long term administration of FT-207 and CQ included many patients with good response.
37例晚期卵巢癌患者接受了喃氟啶（FT - 207）和丝裂霉素（CQ）治疗。这些患者的肿瘤已浸润至盆腔和腹腔，且有远处转移，因此无法进行根治性手术。37例患者中有12例可评估。FT - 207 + CQ是一种治疗晚期卵巢癌的有效联合用药，总有效率为40.9%，完全缓解率为4.5%（1/22），部分缓解率为36.4%（8/22），无变化率为27.3%（6/22），进展率为31.8%（7/22）。腺癌患者的缓解率为66.7%（8/12）。根据分期，Ⅲ期患者的缓解率为50.0%（6/12），Ⅳ期患者的缓解率为37.5%（3/8）。研究中进展期疾病组使用的FT - 207总剂量为38.3g，良好缓解组为177.6g。长期使用FT - 207和CQ的组中有许多缓解良好的患者。
